Gilead highlights Yescarta survival data in ASCO updateGilead’s Kite subsidiary has reported new data from the main trial for its CAR-T Yescarta, hoping to encourage Share XGilead highlights Yescarta survival data in ASCO updatehttps://pharmaphorum.com/news/gilead-highlights-yescarta-survival-data-in-asco-update/
Gilead faces lawsuit over HIV drug pricingGilead and other pharma companies stand accused of engaging in a scheme to block cheaper competitors to life-saving Share XGilead faces lawsuit over HIV drug pricinghttps://pharmaphorum.com/news/gilead-faces-lawsuit-over-hiv-drug-pricing/
Gilead to donate HIV drug to US government prophylaxis schemeGilead has announced it will donate its HIV drug Truvada to a US-government led prophylaxis programme to end Share XGilead to donate HIV drug to US government prophylaxis schemehttps://pharmaphorum.com/news/gilead-to-donate-hiv-drug-to-us-government-prophylaxis-scheme/
NHS trumpets Hep C deal, quietly drops 2025 elimination target after legal rowNHS England has announced a deal with AbbVie, Gilead, and Merck, Sharpe and Dohme (MSD) that aims to eliminate Share XNHS trumpets Hep C deal, quietly drops 2025 elimination target after legal rowhttps://pharmaphorum.com/news/nhs-trumpets-hep-c-deal-quietly-drops-2025-elimination-target-after-legal-row/
Blow for Gilead as another NASH trial failsGilead’s attempts to find a treatment for nonalcoholic steatohepatitis (NASH) have been dealt another blow after another trial Share XBlow for Gilead as another NASH trial failshttps://pharmaphorum.com/news/blow-for-gilead-as-another-nash-trial-fails/
AI firm Insitro signs Gilead as first pharma partner with NASH dealLess than a year after coming out of stealth mode with a $65 million first-round last year, artificial Share XAI firm Insitro signs Gilead as first pharma partner with NASH dealhttps://pharmaphorum.com/digital/ai-insitro-gilead-pharma-partner/
Gilead and Novo Nordisk collaborate for NASH trialGilead and Novo Nordisk have announced that they will collaborate on a clinical trial in nonalcoholic steatohepatitis (NASH) Share XGilead and Novo Nordisk collaborate for NASH trialhttps://pharmaphorum.com/news/gilead-and-novo-nordisk-collaborate-for-nash-trial/
ViiV hopes for blockbuster with HIV drug combo approvalThe FDA has approved ViiV’s Dovato, a single-tablet, two drug HIV drug regimen of dolutegravir and lamivudine for Share XViiV hopes for blockbuster with HIV drug combo approvalhttps://pharmaphorum.com/news/viiv-hopes-blockbuster-hiv-drug-combo-approval/
Gilead files Truvada follow-up Descovy for PrEPGilead Sciences has filed Descovy, its successor to HIV pre-exposure prophylaxis (PrEP) therapy Truvada, in the US, spending Share XGilead files Truvada follow-up Descovy for PrEPhttps://pharmaphorum.com/news/gilead-files-truvada-follow-up-descovy-for-prep/
